Overview

Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing

Status:
Completed
Trial end date:
2013-05-10
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to investigate the effect of romosozumab compared with placebo on time to radiographic healing of fresh tibial diaphyseal fractures (fractures in the midsection of the shinbone).
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Collaborator:
UCB Pharma
Treatments:
Polystyrene sulfonic acid